You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for New Drug Application (NDA): 204017


✉ Email this page to a colleague

« Back to Dashboard


NDA 204017 describes TWIRLA, which is a drug marketed by Agile and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the TWIRLA profile page.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for 204017
Tradename:TWIRLA
Applicant:Agile
Ingredient:ethinyl estradiol; levonorgestrel
Patents:3
Pharmacology for NDA: 204017
Mechanism of ActionEstrogen Receptor Agonists
Physiological EffectInhibit Ovum Fertilization
Suppliers and Packaging for NDA: 204017
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TWIRLA ethinyl estradiol; levonorgestrel SYSTEM;TRANSDERMAL 204017 NDA Agile Therapeutics, Inc. 71671-100 71671-100-01 1 POUCH in 1 CARTON (71671-100-01) / 1 PATCH in 1 POUCH (71671-100-11)
TWIRLA ethinyl estradiol; levonorgestrel SYSTEM;TRANSDERMAL 204017 NDA Agile Therapeutics, Inc. 71671-100 71671-100-03 3 POUCH in 1 CARTON (71671-100-03) / 1 PATCH in 1 POUCH (71671-100-11)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SYSTEM;TRANSDERMALStrength0.03MG/24HR;0.12MG/24HR
Approval Date:Feb 14, 2020TE:RLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Aug 26, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Try a TrialPatent Expiration:Jul 10, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Try a TrialPatent Expiration:Jul 10, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 204017

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Agile TWIRLA ethinyl estradiol; levonorgestrel SYSTEM;TRANSDERMAL 204017-001 Feb 14, 2020 ⤷  Try a Trial ⤷  Try a Trial
Agile TWIRLA ethinyl estradiol; levonorgestrel SYSTEM;TRANSDERMAL 204017-001 Feb 14, 2020 ⤷  Try a Trial ⤷  Try a Trial
Agile TWIRLA ethinyl estradiol; levonorgestrel SYSTEM;TRANSDERMAL 204017-001 Feb 14, 2020 ⤷  Try a Trial ⤷  Try a Trial
Agile TWIRLA ethinyl estradiol; levonorgestrel SYSTEM;TRANSDERMAL 204017-001 Feb 14, 2020 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.